ABHI Accelerator Selection Aims to Accelerate EvoLiver US Deployment

Mursla Bio reported that it was selected for the ABHI US Accelerator, describing the placement as supporting US commercial deployment of its EvoLiver product.

In the announcement, EvoLiver is characterized as an FDA-designated liver cancer surveillance test, and the company also describes it as a blood test designed to improve liver cancer detection in high-risk patients; the program is framed as building on an existing US presence. The update presents accelerator participation as supporting market introduction. The remainder of the announcement focuses on the program’s stated resources and the company’s described launch-readiness activities.

Within the same report, the ABHI US Accelerator is described as providing structured access to more than 300 senior healthcare leaders spanning 35 hospitals, 20 health systems, and US insurers. The stakeholder mix is framed around health-system leadership and payer perspectives rather than a single site or discipline. The program is also described as offering direct operational guidance from Becton Dickinson, Dell Medical School at the University of Texas, and ABHI’s US advisor network. These elements are presented as support intended to help move the product toward integration into US clinical workflows.

The announcement links accelerator participation to how quickly EvoLiver could move from “launch readiness” toward “early adoption,” particularly in specialist hepatology centers, while presenting this as an expectation rather than a dated milestone. Overall, the update keeps the focus on deployment momentum rather than calendar-based commitments.

Operationally, Mursla Bio describes several parallel workstreams it says are underway as part of US launch preparations for EvoLiver. The announcement lists CLIA lab preparation, engagement with key opinion leaders, and outreach to clinical societies as components of this preparation. It also describes payor dialogue as part of the same launch-readiness effort, presented as early engagement rather than a completed coverage outcome. Taken together, these activities are framed as the practical foundation for US launch readiness alongside the accelerator-supported push toward workflow entry.

On positioning and expansion, the company describes its commercial approach as hepatology-led and guideline-aligned, and it links broader expansion to the accrual of additional clinical evidence. In the announcement’s wording, wider coverage and adoption are framed as contingent on that evidence base developing over time, rather than as an assumed near-term outcome. Payer engagement is again presented in the context of ongoing dialogue, while the emphasis remains on aligning deployment with how hepatology services and clinical pathways operate. Across these elements, the update presents evidence generation and payer engagement as priorities running in parallel with efforts to support workflow adoption.

Key Takeaways:

• Selection to the accelerator was reported as a step intended to support US introduction of EvoLiver and engagement with US healthcare stakeholders.
• The accelerator was described as offering structured access to hospital/health-system leaders and insurers plus operational guidance from named partners.
• The announcement described US launch preparations (including CLIA lab readiness and stakeholder engagement) and framed broader expansion as dependent on additional clinical evidence supporting coverage and adoption.